5:40 PM
 | 
Dec 05, 2011
 |  BC Extra  |  Clinical News

Cobicistat-boosted atazanavir meets HIV endpoint

Gilead Sciences Inc. (NASDAQ:GILD) said cobicistat-boosted atazanavir plus Truvada emtricitabine/tenofovir met the primary endpoint of non-inferiority to ritonavir-boosted atazanavir plus Truvada in the Phase III Study 114 trial to treat...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >